The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 25, 2025 for Ravi Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ravi Agrawal, trustee of Ravi Agrawal Trust and a promoter of Ajanta Pharma, has disclosed under SEBI SAST Regulations the simultaneous creation of a pledge on 40,000 equity shares and release of a pledge on 40,000 equity shares, both dated September 24, 2025. The new pledge was created in favour of Infina Finance Private Limited, while the released pledge was held by Deutsche Investments India Private Limited, both citing business financing as the reason. His pre-event holding stood at 1,62,42,904 shares (13.00%) with 60,07,642 shares (4.81%) already encumbered, and the encumbrance level returned to 4.81% post-event. This is effectively a rollover of pledge from one lender to another with a negligible change in shares.
This is a routine pledge rollover with no meaningful change in promoter ownership or encumbered holding; shareholders should not expect any material impact on stock price or promoter control.